Research library

Key finding

Laboratory and animal experiments linked Selank's anxiolytic activity to concentration-dependent allosteric modulation of GABA receptors.

Key finding

In 16 people with chronic insomnia, DSIP produced modest improvements in objective sleep efficiency and latency, although the broader effects were weak and not consistently different from placebo.

Key finding

Selank administration altered expression of genes involved in GABAergic neurotransmission, supporting a molecular pathway for its observed anxiolytic activity.

Key finding

In a crossover sleep study, DSIP reduced awakenings and sleep latency and increased total and NREM sleep versus baseline, but the differences from placebo were not significant.

Key finding

In rats exposed to unpredictable chronic stress, Selank reduced anxiety-like behaviour and enhanced the anxiolytic effect of diazepam.

Key finding

The study reports that the study underscores DSIP-CBBBP potential in correcting neurotransmitter dysregulation and promoting sleep, hinting at its utility in sleep-related therapies.

Key finding

The study reports that resting-state fMRI was carried out three times, namely before, after 5 and 20 min of the injection of either Semax, or Selank, or placebo.

Key finding

The study reports that since the turn of the century, it has been postulated that humoral factors induce sleep.

Key finding

The results extend therapeutic possibilities of treatment of anxietyspectrum disorders with the combination of benzodiazepine tranquilizers and selank.

Key finding

Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied.

Key finding

To study the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam.

Key finding

Activity of a peptide tuftsin analogue Selank was studied in outbred rats using the naloxone-precipitated morphine withdrawal model.

Key finding

The effects of a peptide anxiolytic Selank synthesized on the basis of the endogenous peptide tuftsin on memory impairment and content of brain-derived neurotrophic factor (BDNF) in brain structures were analyzed in outbred rats receiving 10% ethanol as the only source of fluid for 30 weeks.

Key finding

The effect of single and course administration of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) in the dose 200 microg/kg on the rat hippocampus transcriptional profile were studied using cDNA microarray technology.

Key finding

This publication examines transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide selank.

Key finding

The purpose of this article was to study the immunotropic effects of the new neurotrophic heptapeptide selank.

Key finding

Pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank (300 μg/kg/day for 5 days), known to possess anxiolytic and nootropic properties, were compared by studying the elevated-plus-maze behavior of inbred BALB/c and C57BL/6 mice and measuring the binding of markers to NMDA and GABA receptors.

Key finding

Previous studies have shown that synthetic tuftsin analogue Selank and its fragments cause a number of alterations in the expression of certain genes involved in inflammation in mouse spleen.

Key finding

It has been shown that the peptide anxiolytic drug Selank recovers learning and memory impaired by damage of the noradrenergic (NA) brain system in Wistar rats after injection of the NA-synthesis inhibitor disulfiram, administration of neurotoxic compound 6-OHDA, or a combined induction of hypoxic hypoxia and hypercapnia.

Key finding

The work presents results of study of role of heptapeptide Selank--an anxiolytic from group of biologically active peptides--in compensation of disturbed psychic and homeostatic functions in monkeys.